UTX gene mutation “robs” individuals of natural cancer protection 10 November 2021 | By Anna Begley (Drug Target Review) The UTX gene mutation was found to lead to an increased cancer risk, presenting a potential drug target for preventative therapies.
Scientists explore CA2 neuron mitochondria for memory loss targets 10 November 2021 | By Anna Begley (Drug Target Review) The team will receive $2 million over five years to investigate the CA2 brain region for the development of neurological therapies.
Novel intestine chip enables effective in vitro study of COVID-19 therapies 10 November 2021 | By Anna Begley (Drug Target Review) The intestine chip was infected with a coronavirus to test a variety of drugs, presenting a new method to investigate COVID-19 treatments.
Researchers achieve DNA methylation removal in mouse models 9 November 2021 | By Anna Begley (Drug Target Review) The study showed that DNA “de-methylation” activity can be targeted to anywhere in the DNA and may be a new therapeutic strategy.
MicroRNA in red blood cells causes vascular damage in type 2 diabetes 9 November 2021 | By Anna Begley (Drug Target Review) Researchers discovered that cardiovascular damage was caused by reduced microRNA-210 levels in patient cells and mice with type 2 diabetes.
Soluble fibrinogen a potential target for neurodegeneration 9 November 2021 | By Anna Begley (Drug Target Review) In a pre-clinical study, fibrinogen increased the death of mouse brain neurons, suggeting fibrin can have similar toxic effects on neurons.
bit.bio raises $103 million in first close of Series B financing 9 November 2021 | By bit.bio The funding will accelerate clinical development of cell therapies using breakthrough gene engineering technology opti-oxTM.
IL-36Ra discovery may help heal skin wounds from ischemia reperfusion 8 November 2021 | By Anna Begley (Drug Target Review) The absence of interleukin-36 receptor antagonist (IL-36Ra) significantly slowed down wound healing in ischemia-reperfusion injuries in mice.
ABI3 gene may be the key to new Alzheimer’s disease therapies 8 November 2021 | By Anna Begley (Drug Target Review) The study found that deleting the ABI3 gene in mice increased plaques and inflammation in the brain, suggesting avenues for new treatments.
Researchers identify RNA molecule that suppresses prostate tumours 8 November 2021 | By Anna Begley (Drug Target Review) Scientists discover a long noncoding RNA, termed NXTAR, and a small molecule drug that could be used to treat prostate cancer.
Tropical frog models reveal novel kidney disease insights 5 November 2021 | By Anna Begley (Drug Target Review) Scientists utilised CRISPR technology and deep learning systems to investigate the genes associated with polycystic kidney disease.
Fruit flies could unveil new genetic targets for obesity treatment 5 November 2021 | By Anna Begley (Drug Target Review) Researchers used obese fruit flies to analyse how gene activities affect triacylglyceride levels, unveiling novel drug targets for obesity.
New class of CAR T cells combat previously “untargetable” cancer drivers 4 November 2021 | By Anna Begley (Drug Target Review) The peptide-centric chimeric antigen receptors killed neuroblastoma cells in mice and could potentially expand the pool of immunotherapeutic targets.
Alterity’s ATH434 improves Parkinson’s-related gastrointestinal dysfunction 4 November 2021 | By Anna Begley (Drug Target Review) ATH434 reversed some of the gastrointestinal damage to the enteric nervous system associated with Parkinson's disease in a pre-clinical study.
Experimental drug boosts immunotherapy efficacy for pancreatic cancer 4 November 2021 | By Anna Begley (Drug Target Review) An experimental drug enhanced the benefit of immunotherapy, reducing and in some cases eliminating pancreatic cancer in mice.
